Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy.
Al-Nawakil
Chadi
C
Tamburini
Jerome
J
Bardet
Valerie
V
Chapuis
Nicolas
N
Bourry
Edward
E
Roux
Christian
C
Park
Sophie
S
Choquet
Sylvain
S
Dreyfus
François
F
Bouscary
Didier
D
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000627:therapeutic use; D012074:Remission Induction / Q000379:methods; D016896:Treatment Outcome
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D004317:Doxorubicin